---
title: "ABSI.US (ABSI.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ABSI.US/news.md"
symbol: "ABSI.US"
name: "ABSI.US"
parent: "https://longbridge.com/en/quote/ABSI.US.md"
datetime: "2026-05-21T01:50:02.702Z"
locales:
  - [en](https://longbridge.com/en/quote/ABSI.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ABSI.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ABSI.US/news.md)
---

# ABSI.US (ABSI.US) — Related News

### [HC Wainwright Has Optimistic Outlook of Absci Q3 Earnings](https://longbridge.com/en/news/286260136.md)
*2026-05-13T12:22:57.000Z*
> HC Wainwright has raised its Q3 2026 EPS estimate for Absci Corporation (NASDAQ:ABSI) from ($0.23) to ($0.22) per share.

### [AbSci (ABSI) Receives a Rating Update from a Top Analyst](https://longbridge.com/en/news/286159023.md)
*2026-05-12T21:05:57.000Z*
> Debanjana Chatterjee from JonesTrading has maintained a Buy rating on AbSci (ABSI) with a price target of $11.00. Chatte

### [AbSci Price Target Raised to $11 as Analyst Reiterates Buy on Promising PRLR Pipeline and ABS-201 Data](https://longbridge.com/en/news/286158529.md)
*2026-05-12T21:05:38.000Z*
> Analyst Debanjana Chatterjee from JonesTrading has reiterated a Buy rating on AbSci, raising the price target to $11.00 

### [Absci Corp. Charts High-Stakes Path With ABS-201](https://longbridge.com/en/news/285858462.md)
*2026-05-11T00:25:51.000Z*
> Absci Corp. held its Q1 earnings call, highlighting progress on ABS-201, a promising treatment with a potential U.S. mar

### [12 Health Care Stocks Moving In Friday's Pre-Market Session](https://longbridge.com/en/news/285722413.md)
*2026-05-08T12:05:56.000Z*
> In Friday's pre-market session, Traws Pharma (NASDAQ:TRAW) shares surged 37% to $2.33, while Amylyx Pharmaceuticals (NAS

### [](https://longbridge.com/en/news/285726274.md)
*2026-05-08T11:58:52.000Z*
> Absci shares are trading lower after the company reported mixed Q1 financial results.

### [Brendan Smith Reiterates Buy on AbSci, Citing Emerging PRLR Franchise and Multiple Upcoming Clinical Catalysts](https://longbridge.com/en/news/285653707.md)
*2026-05-08T02:25:19.000Z*
> TD Cowen analyst Brendan Smith has reiterated a Buy rating on AbSci (ABSI) stock, citing the company's emerging prolacti

### [Absci | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 215 K](https://longbridge.com/en/news/285617682.md)
*2026-05-07T20:53:39.000Z*
### [Absci | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 215 K](https://longbridge.com/en/news/285616951.md)
*2026-05-07T20:49:33.000Z*